Boehringer Ingelheim's Nintedanib Isn't Major Threat to InterMune (ITMN) - Summer Street

January 31, 2014 1:00 PM EST
Get Alerts ITMN Hot Sheet
Price: $73.89 --0%

Rating Summary:
    8 Buy, 9 Hold, 0 Sell

Rating Trend: = Flat

Today's Overall Ratings:
    Up: 0 | Down: 2 | New: 5
Trade Now! 
Join SI Premium – FREE
Boehringer Ingelheim's nintedanib drug isn't a major competitive threat to InterMune Inc. (Nasdaq: ITMN), said Summer Street analysts in a note Friday.

"Some investors are concerned that the Phase III results from Boehringer Ingelheim's nintedanib in idiopathic pulmonary fibrosis could be a spoiler if the trials (INPULSIS-1 and -2) are successful. We believe that if Boehringer's drug gets to market, nintedanib will not be a major competitive threat to ITMN because both products will likely have a limited duration of action so patients will be cycled from one drug to another. Furthermore ITMN's drug may be the most tolerable and preferred by patients. Finally it may actually work in ITMN’s favor to have a second company promoting treatment of IPF. The biggest risk to ITMN, if pirfenidone becomes FDA approved, could be a slow launch as is occurring in Europe. Having a second company promoting treatment of IPF could speed the launch. The market is clearly large enough to create profits for several competitors," said Summer Street.

InterMune is a Top Pick on Summer Street's Alpha List.


Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In





Related Categories

Analyst Comments, Fed, Hot Comments, Trader Talk

Related Entities

Piper Jaffray Alpha List